Breaking News, Financial News

Financial Report: Merck

Singulair expiry continues to impact results

Merck

1Q Revenues: $10.7 billion (-9%)

1Q Earnings: $1.6 billion (-9%)

Comments: Pharmaceutical sales were $8.9 billion (-12%) due to patent expiries for Singulair, Maxalt and Clarinex. Gardasil sales were up 37% to $390 million. Remicade sales were up 5% to $549 million, Simponi sales were up 46% to $108 million. Isentress sales were up 8% to $362 million. Zetia sales were up 2% to $629 million. Consumer Care and Animal Health revenues were up 4% to $571 million and $840 million, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters